BioFunding, UKUK

Successful placing of shares

25.01.2007

London – The British pharmaceutical company Protherics plc has issued 58 715 544 new ordinary shares for Euro 54 million to finance the company’s growth. Only recently, Protherics had acquired the US firm Macromed Inc. in a Euro 20 million all-share deal. Furthermore, Chairman Stuart Wallis announced that he has signed two other agreements, which expand the company’s drug pipeline: Protherics in-licensed intellectual property from Glenveigh Pharmaceutical and paid Euro 2.8 million in stock. With the third deal, Protherics took over co-development rights for Acadesine from Advanced In Vitro Cell Technologies SL for an undisclosed sum. The drug is a potential cure for chronic B-cell lymphocatic leukaemia. Protherics has already two marketed products with CroFab (pit viper antivenom) and DigiFab, a digoxin antidote, which is sold in the US through an Altana subsidiary.

UKUK

24.11.2011

London – The European Medicines Agency has recalled all batches of the cancer drugs Busilvex, Velcade and Vidaza manufactured at Boehringer Ingelheim’s Ben Venue Laboratories facility in Bedford, Ohio, from the European market....

UKUK

14.11.2011

London – GlaxoSmithKline goes west. The British pharmaceutical company launched the $50-million GSK Canada Life Sciences Innovation Fund that will invest in “early-stage breakthrough research” in health care life science in...

UKUK

04.10.2011

Heidelberg/Cambridge/London– A team of researchers from GlaxoSmithKline, the biotech company Cellzome and from Universities Cambridge, Ulm and Amsterdam have found a promising treatment for mixed lineage (MLL-fusion) leukaemia...

UKUK

01.10.2011

Amersham – GE Healthcare intends to remain a major force in cancer therapy. Based in London, the health business of the US technology giant announced it will be reserving €730m of its total R&D budget over the next five years for...

UKUK

01.10.2011

Wolverhampton – One of the challenges for manufacturers of probiotic foods is getting large enough numbers of the bacteria into the intestines; most perish under the strongly acidic conditions in the stomach. Scientists from the...

UKUK

01.10.2011

Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based...

UKUK

26.09.2011

London – The first clinical trial using human embryonic stem cells will be carried out at the Moorfields Eye hospital in London. Doctors will inject retinal cells into the eyes of 12 patients with Stargardt‘s macular dystrophy, a...

UKUK

20.09.2011

Amersham – GE Healthcare intends to stay a major force in cancer. The health business of the US-technological company, which is based in London, announced to reserve €730m of its total R&D budget over the next five years for...

UKUK

29.08.2011

Cambridge - A new biotech spin off from the University of Cambridge launched with €6.8m venture capital. Newco Mission Therapeutics Ltd. plans to develop cancer drugs targeting enzymes in ubiquitin pathways that control cellular...

Displaying results 21 to 30 out of 396

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/2/article/successful-placing-of-shares.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.98 EUR0.00%
  • ACTELION113.50 CHF0.00%
  • ADDEX3.19 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.98 EUR0.00%
  • ACTELION113.50 CHF0.00%

TOP

  • BIOFRONTERA2.82 EUR15.6%
  • BB BIOTECH166.45 EUR11.2%
  • HBM91.50 CHF8.6%

FLOP

  • MAGFORCE5.55 EUR-19.0%
  • PAION2.80 EUR-14.6%
  • CO.DON2.65 EUR-13.1%

TOP

  • SANTHERA89.00 CHF2182.1%
  • CO.DON2.65 EUR150.0%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 31.10.2014

Current issue

All issues